Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precancerous Conditions 3Breast Neoplasms 3Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenomatous Polyposis Coli 2Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Intraductal Neoplasms 1Pain 1Melanoma 1Leukemia, Myeloid, Acute 1Inflammation 1Hypertension 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Sulindac × Clear all
NCT00755976 2014-12-31

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Cancer Trials Ireland

Phase 2 Completed
32 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡